|
|
Article: Eyetech, Pfizer Go Before FDA Panel With Macugen.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Eyetech Pharmaceuticals Inc. and partner Pfizer Inc. today are scheduled to present data supporting use of the potential blockbuster Macugen as a treatment for neovascular or wet age-related macular degeneration.
The partners will go before the Dermatologic and Ophthalmic Drugs Advisory Committee, which has been asked to decide, among other things, whether the trial data are sufficient and if the benefits of using Macugen outweigh the risks. The FDA is not bound by the panel's recommendations.
Already the agency awarded the New York-based firms priority-review status on the rolling new drug application filed June 17 under ...
Related newspaper, magazine, and journal articles:
|
|
Article: ARMED WITH MACUGEN, EYETECH JOINS IPO QUEUE, SEEKS $100M.
BIOWORLD Today;
September 16, 2003 ;
700+ words
... ... are more receptive. (See BioWorld Today, Aug. 29, 2003.) New ... itself and its lead drug, Macugen, through its potential ... would earn royalties. (See BioWorld Today, Dec. 19, 2002.) Macugen (pegaptanib sodium), an ...
|
|